TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31542745

Group type: EXPERIMENTAL
Intervention: NHS HC invitation
Number of subjects: 366005
Study: 25482145

Group type: EXPERIMENTAL
Intervention: Carfilzomib with lenalidomide and dexamethasone
Number of subjects: 792

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (control group)
Number of subjects: 792
Study: 23193213

Group type: EXPERIMENTAL
Intervention: Fasting state (placebo)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fasting state (metreleptin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isocaloric diet
Number of subjects: 6
Study: 22069286

Group type: EXPERIMENTAL
Intervention: Anti-CD3 (Otelixizumab; ChAglyCD3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18308009

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU; 80 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16572041

Group type: EXPERIMENTAL
Intervention: Self-sampling with tampons
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-sampling with vaginal swabs
Number of subjects: 450

Group type: COMPARATOR
Intervention: Clinician sampling during speculum examination
Number of subjects: 450
Study: 12679437

Group type: EXPERIMENTAL
Intervention: Glyburide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated diabetes
Number of subjects: 0
Study: 11191009

Group type: EXPERIMENTAL
Intervention: Domperamol (fixed combination of domperidone and paracetamol)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 120
Study: 8772902

Group type: EXPERIMENTAL
Intervention: Isoniazid 10 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoniazid 5 mg/kg
Number of subjects: 20
Study: 1993561

Group type: EXPERIMENTAL
Intervention: Minoxidil gel
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nonresponders (younger than 35 years)
Number of subjects: 168
Study: 6362343

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study: 30825302

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training in the horizontal direction for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation for 30 min, 3 days per week for 6 weeks)
Number of subjects: 21
Study: 30261084

Group type: EXPERIMENTAL
Intervention: Omission of ACEI therapy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Continuation of ACEI therapy
Number of subjects: 275
Study: 26983411

Group type: EXPERIMENTAL
Intervention: Percutaneous pedicle screw fixation at the fractured vertebra
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no placement of pedicle screws into the fractured vertebra)
Number of subjects: 32
Study: 24809233

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 3 mg tacrolimus powder for 15 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rectal administration of 15 mg tacrolimus suppository
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral administration of 7 mg tacrolimus capsules (Prograf)
Number of subjects: 18
Study: 21594575

Group type: EXPERIMENTAL
Intervention: Huggy‐Puppy intervention (HPI)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Revised Huggy‐Puppy intervention (HPI-r)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting list comparison group (WL)
Number of subjects: 104
Study: 19329465

Group type: EXPERIMENTAL
Intervention: Periodontal therapy and oral hygiene instruction in the third trimester
Number of subjects: 83

Group type: COMPARATOR
Intervention: No periodontal treatment (Control)
Number of subjects: 83
Study: 17447869

Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo control intervention
Number of subjects: 124
Study: 15177793

Group type: EXPERIMENTAL
Intervention: Pantomime (P)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Imitation (concurrent (CI) and delayed (DI))
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MMSE scores
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patterns of apraxia
Number of subjects: 62
Study: 11779723

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9844957

Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nocturnal serum leptin in patients with depression
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nocturnal cortisol secretion in patients with depression
Number of subjects: 15

Group type: COMPARATOR
Intervention: No significant differences in plasma GH and ACTH
Number of subjects: 15

Group type: COMPARATOR
Intervention: Correlation of serum leptin with BMI in controls
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nocturnal leptin surge in young female patients
Number of subjects: 15
Study: 9836109

Group type: COMPARATOR
Intervention: 3 MU alpha 2b-interferon
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 6 MU alpha 2b-interferon
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 6 MU alpha 2b-interferon in cirrhotic patients
Number of subjects: 80
Study: 2564782

Group type: EXPERIMENTAL
Intervention: Atracurium (0.92‐0.98 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.16‐0.18 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no neuromuscular blocking drugs
Number of subjects: 0
Study: 606784

Group type: EXPERIMENTAL
Intervention: Whole-virus vaccines
Number of subjects: 253

Group type: COMPARATOR
Intervention: Split-product vaccines
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: All vaccine preparations
Number of subjects: 253
Study: 31092248

Group type: EXPERIMENTAL
Intervention: Aligning headlines and main causal claims with the underlying evidence
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Inserting explicit statements/caveats about inferring causality
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 312
Study: 27831828

Group type: EXPERIMENTAL
Intervention: Guideline-based management (NAEPP guidelines)
Number of subjects: 143
Study: 26112148

Group type: EXPERIMENTAL
Intervention: Heating and cooling combination therapy (OCH-S100), 10 treatments (15 min each) over 4 weeks, consisting of five cycles of heating/cooling therapy (max: 45 °C, min: 15 °C).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham therapy, 10 treatments (15 min each) over 4 weeks, consisting of five cycles of sham therapy (max: 1 °C above skin temperature, min: 1 °C below skin temperature).
Number of subjects: 80
Study: 24156206

Group type: EXPERIMENTAL
Intervention: 8% arginine, calcium carbonate and 1,000 ppm fluoride dentifrice
Number of subjects: 86

Group type: COMPARATOR
Intervention: 1,000 ppm fluoride dentifrice
Number of subjects: 86
Study: 21711215

Group type: EXPERIMENTAL
Intervention: Modified therapeutic community aftercare (MTC‐A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard aftercare (C)
Number of subjects: 76
Study: 19550192

Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum received one month before assessment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control group received the same curriculum three months later
Number of subjects: 69
Study: 16408206

Group type: EXPERIMENTAL
Intervention: rHEPO (10,000 IU s.c. three times a week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rHEPO+G‐CSF (10,000 IU rHEPO s.c. three times a week + 300 mug G‐CSF s.c. twice a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: rHEPO
Number of subjects: 30

Group type: COMPARATOR
Intervention: rHEPO+G‐CSF
Number of subjects: 30
Study: 15250845

Group type: EXPERIMENTAL
Intervention: Dietary counselling (3 sessions over 4 months)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care (dietary assessment and pamphlets)
Number of subjects: 189
Study: 11420777

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 9250230

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141) received antibiotic-related suggestions from an infectious disease fellow and a clinical pharmacist.
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (n = 111) did not receive antibiotic-related suggestions.
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141)
Number of subjects: 252
Study: 8099802

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg nizatidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine plus 100 mg pirenzepine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3332556

Group type: EXPERIMENTAL
Intervention: Unopposed 17 beta-estradiol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sequential combination with progestagen
Number of subjects: 144

Group type: COMPARATOR
Intervention: 24R,25-(OH)2D3
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 30244669

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo low-level laser therapy (LLLT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 78
Study: 29884067

Group type: EXPERIMENTAL
Intervention: SPACE intervention (educator physical activity training, provision of portable play equipment, modified outdoor schedule of 4 × 30‐minute periods)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SPACE intervention
Number of subjects: 200
Study: 26934687

Group type: EXPERIMENTAL
Intervention: Ten 1-min high-intensity intervals (90% VO2 peak, 1 min recovery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Five 2-min high-intensity intervals (80-100% VO2 peak, 1 min recovery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23129105

Group type: EXPERIMENTAL
Intervention: Mindfulness-based body scan (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Reading about natural history (control group, n = 28)
Number of subjects: 55
Study: 23238504

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25 Gy in 5 fractions) and postoperative chemotherapy (5-fluorouracil and leucovorin)
Number of subjects: 278

Group type: COMPARATOR
Intervention: TME alone (surgery group)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 278
Study: 20564352

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐lambda at 1.5 or 3.0 microg/kg administered every 2 weeks or weekly for 4 weeks (Part 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Weekly doses of PEG‐IFN‐lambda ranging from 0.5 to 2.25 microg/kg in combination with ribavirin (RBV) for 4 weeks (Part 2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Weekly PEG‐IFN‐lambda at 1.5 microg/kg in combination with RBV for 4 weeks (Part 3)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐lambda with or without RBV for 4 weeks
Number of subjects: 56
Study: 18304051

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for troponin I (cTnI) measurement
Number of subjects: 860

Group type: COMPARATOR
Intervention: Central hospital laboratory testing (CHLT)
Number of subjects: 860
Study: 16003290

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 30
Study: 12447009

Group type: EXPERIMENTAL
Intervention: 0.125% dextrin sulfate (DS) gel
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 73
Study: 10359883

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7738624

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 1714
Study: 2143592

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 24
Study: 550158

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (prostaglandin synthesis inhibitor)
Number of subjects: 0
Study: 31488213

Group type: EXPERIMENTAL
Intervention: Iloprost 1 ng/kg/min and eptifibatide 0.5 μg/kg/min for 48 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28941976

Group type: EXPERIMENTAL
Intervention: Combined dietary docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and gamma‐linolenic acid (GLA) supplementation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 26721008

Group type: EXPERIMENTAL
Intervention: 5mg rosuvastatin
Number of subjects: 82

Group type: COMPARATOR
Intervention: 10mg rosuvastatin
Number of subjects: 82
Study: 22791299

Group type: EXPERIMENTAL
Intervention: Screening programme using ambulant intermittent electrocardiogram (ECG) recording to detect silent AF
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Screening programme
Number of subjects: 25000
Study: 22783713

Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 28
Study: 19736900

Group type: EXPERIMENTAL
Intervention: 40 mg oxycodone administered intravenously over 2 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg oxycodone administered intravenously over 15 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 mg oxycodone administered intravenously
Number of subjects: 12
Study: 17903627

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 29
Study: 15553287

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Tetric Flow)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (Z100)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Packable resin composite (Solitaire 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Organically modified ceramics‐ormocer (Admira)
Number of subjects: 20
Study: 11575408

Group type: EXPERIMENTAL
Intervention: Remifentanil-desflurane anaesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fentanyl-desflurane anaesthesia
Number of subjects: 44
Study: 9231604

Group type: EXPERIMENTAL
Intervention: Prospective evaluations by trained clinical trial examiners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective surgical chart reviews
Number of subjects: 0
Study: 7961576

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Haloperidol (previous studies)
Number of subjects: 18
Study: 3127965

Group type: EXPERIMENTAL
Intervention: Oxamniquine at 20 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine at 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine at 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel at 20 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel at 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel at 40 mg/kg
Number of subjects: 0
Study: 31451351

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS, 590 mg QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, 300 mg BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 0
Study: 29145631

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 3 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27062955

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 68
Study: 25997527

Group type: EXPERIMENTAL
Intervention: GDM macrosomia group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 60
Study: 23709655

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 20470299

Group type: EXPERIMENTAL
Intervention: Twice daily icodextrin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Once daily icodextrin
Number of subjects: 28
Study: 18986359

Group type: EXPERIMENTAL
Intervention: S/S genotype of HTTLPR polymorphism in 5-HTT gene
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 12/12 genotypes of VNTR polymorphism
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: State and Trait Anxiety Inventory tests (STAI-I and STAI-II)
Number of subjects: 100
Study: 16634988

Group type: EXPERIMENTAL
Intervention: Sibutramine with cognitive-behavioural weight loss treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cognitive-behavioural weight loss treatment alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 73
Study: 12830996

Group type: EXPERIMENTAL
Intervention: Noninvasive technique to evaluate flow‐mediated vasodilation on the brachial artery
Number of subjects: 0
Study: 10795944

Group type: EXPERIMENTAL
Intervention: Subtype targeted intervention approach
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Cluster analyses using the Pros, Cons, and Situational Temptations from the Transtheoretical Model
Number of subjects: 4144

Group type: COMPARATOR
Intervention: Previous research on stage-tailored and individualized interventions
Number of subjects: 4144
Study: 8815168

Group type: EXPERIMENTAL
Intervention: D-ribose (60 g daily for 7 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 1386652

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231
Study: 6436879

Group type: EXPERIMENTAL
Intervention: Ultra-low yielding cigarette (0.1 mg nicotine) for 10 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual brand cigarette
Number of subjects: 26
Study: 31489621

Group type: EXPERIMENTAL
Intervention: Non-fundal LNG-IUS insertion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fundal LNG-IUS insertion
Number of subjects: 92
Study: 28370266

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 220 mcg dry powder inhalation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26978751

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12‐based probiotic complex during 30 days in combination with nasal douche
Number of subjects: 219

Group type: COMPARATOR
Intervention: Nasal douche alone
Number of subjects: 219
Study: 23954763

Group type: COMPARATOR
Intervention: Emotionally charged pictures (erotica, neutral, mutilation) presented in 4 blocks; physiological-emotional reactions assessed in the absence of pain and during pain modulation.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Emotional modulation of pain assessed during the presentation of emotionally charged pictures.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nociceptive flexion reflex (NFR) evoked by suprathreshold electric stimulations.
Number of subjects: 28
Study: 21369549

Group type: EXPERIMENTAL
Intervention: Continuous Negative Pressure (CNP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham CNP
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no shell or wrap)
Number of subjects: 8
Study: 19373824

Group type: EXPERIMENTAL
Intervention: Well Woman Program (WWP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 0
Study: 17134946

Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham respiratory muscle unloading (placebo)
Number of subjects: 6
Study: 14747210

Group type: EXPERIMENTAL
Intervention: cPPG >150 mg/dl
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Oral agents
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1827
Study: 11487072

Group type: EXPERIMENTAL
Intervention: Hybrid laser treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 46
Study: 9633066

Group type: EXPERIMENTAL
Intervention: Fractal coated electrode (Biotronik SD‐V137)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control electrode (TIR-leads with a surface area of 10 mm2 and a 'fractal' coating of titanium nitride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control electrode (TIR-leads)
Number of subjects: 10
Study: 7936248

Group type: EXPERIMENTAL
Intervention: Monocular stimulation in albinos
Number of subjects: 9

Group type: COMPARATOR
Intervention: Monocular stimulation in healthy controls
Number of subjects: 9
Study: 3169116

Group type: EXPERIMENTAL
Intervention: Inhaled adenosine at a concentration of 5 mg.ml‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infusion of a comparable dose of adenosine
Number of subjects: 0
Study: 31253145

Group type: EXPERIMENTAL
Intervention: Volar plating (surgical treatment with open reduction and internal fixation using volar locking plates)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment (closed reduction and plaster immobilization)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Volar plating
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study: 28403911

Group type: EXPERIMENTAL
Intervention: Usual care with monthly social assistance, domotic, and remote assistance
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320